GleamWall
中文EN

MGNX MACROGENICS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1125345 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY22.8%
TTM net income YoY32.1%
TTM EPS YoY33.9%
Revenue 3-yr CAGR-2.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-70.2%
Net margin-45.4%
FCF margin-36.4%
EBITDA margin-66.4%

Returns

ROE-111.8%
ROA-17.5%
ROIC (approx.)—
Asset turnover0.39x

Leverage & solvency

Liabilities / assets92.1%
Debt / equity0.00x
Current ratio2.75x
Interest coverage-4.52x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$18.67M$32.83M$20.77M$41.23M$53.00M$6.87M$13.19M$19.35M
Cost of revenue———$0$0$0$0$233,000
Gross profit———$41.23M$53.00M$6.87M$13.19M$19.12M
R&D expense$30.61M$38.78M$34.97M$33.97M$32.71M$40.79M$39.70M$38.89M
SG&A expense$8.36M$7.90M$9.71M$9.23M$9.90M$9.30M$10.72M$27.81M
Operating income-$20.30M-$13.85M-$33.44M-$12.10M$10.39M-$43.22M-$42.62M-$52.84M
Interest expense$4.08M$4.40M$4.89M$4.27M$3.34M$802,000$91,000-$24,000
Pretax income-$21.48M-$69.64M—-$14.93M$8.57M-$42.61M—-$14.48M
Income tax$0$0—-$777,000$0$105,000—$944,000
Net income-$20.08M$19.52M-$36.77M-$14.15M$16.82M-$36.25M-$41.04M-$15.42M
EBITDA-$20.10M-$13.14M-$31.75M-$10.39M$12.18M-$41.32M-$40.85M-$50.78M
EPS (basic)-0.320.31-0.58—0.27-0.57-0.65—
EPS (diluted)-0.320.31-0.58—0.27-0.57-0.65—
Weighted avg. shares (diluted)63.74M63.59M63.45M—63.28M63.14M62.97M—
Balance sheet
Cash & equivalents$49.03M$113.91M$66.52M$57.22M$80.13M$130.69M$145.57M$182.84M
Receivables$435,000$24.60M$10.43M$427,000$69.23M$12.53M$10.54M$4.31M
Inventory——$9.50M$7.91M$8.75M$9.28M$9.43M$0
Current assets$295.08M$321.69M$182.52M$219.94M$232.09M$204.94M$182.09M$217.49M
PP&E, net$2.23M$2.39M$11.49M$2.10M$13.97M$15.36M$16.88M$18.10M
Total assets$318.69M$345.41M$217.87M$256.85M$270.76M$245.42M$224.56M$261.65M
Current liabilities$107.23M$108.81M$95.94M$43.12M$44.47M$39.00M$55.44M$55.53M
Total liabilities$293.53M$302.54M$196.68M$201.25M$203.76M$198.80M$145.45M$145.60M
Shareholders' equity$25.15M$42.87M$21.20M$55.59M$67.00M$46.62M$79.12M$116.06M
Shares outstanding63.88M63.65M63.56M63.32M63.26M63.21M63.09M62.82M
Cash flow statement
Operating cash flow-$6.33M-$40.75M-$35.81M$43.02M-$30.19M-$46.98M-$46.89M-$38.41M
Capital expenditure$72,000$806,000$344,000$244,000$426,000$715,000$529,000$620,000
Free cash flow-$6.40M-$41.55M-$36.16M$42.78M-$30.61M-$47.70M-$47.42M-$39.03M
Investing cash flow-$59.14M$27.96M$45.32M-$65.99M-$20.37M-$37.64M$9.90M$41.47M
Financing cash flow$590,000$60.17M-$207,000$57,000$0$69.74M-$282,000$155,000
Depreciation & amortization$199,000$708,000$1.69M$1.71M$1.79M$1.91M$1.77M$2.05M
Stock-based compensation$2.06M$1.97M$2.65M$2.66M$3.55M$3.69M$4.39M$11.27M

Free plan shows the latest 8 periods; Pro shows all 59 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.